Immunosuppressants drugs - versus placebo - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.70 [0.58, 0.84]< 12%10 studies (10/-)100.0 %lowlow highcrucial-
death or transfer to ICU 0.97 [0.50, 1.88]< 10%1 study (1/-)53.6 %NAnot evaluable crucial-
deaths 0.75 [0.62, 0.89]< 113%16 studies (16/-)99.9 %some concernlow moderatecrucial-
deaths (time to event analysis only) 0.77 [0.59, 1.02]< 151%5 studies (5/-)96.6 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.64 [0.40, 1.03]< 174%5 studies (5/-)96.7 %lowserious highimportant-
clinical improvement 1.17 [1.08, 1.28]> 10%10 studies (10/-)100.0 %lowlow highimportant-
clinical improvement (14-day) 1.31 [1.13, 1.52]> 10%3 studies (3/-)100.0 %lownot evaluable highimportant-
clinical improvement (28-day) 1.33 [0.95, 1.87]> 10%4 studies (4/-)95.3 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.14 [1.03, 1.27]> 10%4 studies (4/-)99.4 %lownot evaluable highimportant-
death or ventilation 0.73 [0.62, 0.87]< 16%6 studies (6/-)100.0 %some concernnot evaluable moderateimportant-
hospital discharge 1.05 [0.88, 1.25]> 113%2 studies (2/-)70.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.62 [0.46, 0.84]< 10%5 studies (5/-)99.9 %lowserious highimportant-
ICU admission 0.48 [0.25, 0.94]< 10%1 study (1/-)98.4 %NAnot evaluable non important-
recovery 1.57 [0.77, 3.20]> 10%1 study (1/-)89.3 %NAnot evaluable non important-

safety endpoints 00

related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
serious adverse events 0.91 [0.75, 1.11]< 10%6 studies (6/-)83.0 %some concernserious moderateimportant-
superinfection 0.50 [0.32, 0.79]< 10%1 study (1/-)99.8 %NAnot evaluable important-
adverse events 1.09 [0.81, 1.46]< 124%6 studies (6/-)29.5 %some concernserious moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.